Schizophrenia Clinical Trial
— STROOPOfficial title:
Evaluation of Stroop Effect in Patients With Schizophrenia
The main objective of this study is to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
Status | Recruiting |
Enrollment | 80 |
Est. completion date | June 2019 |
Est. primary completion date | October 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: For both: - MMSE score greater than or equal to, 22 if no grade ; 23 if study certificate or CAP or college without patent ; 25 if patent or school without the tray ; 26 or more when bin - IQ = 75 (fNART) - Lextale score = 28 - Age: between 18 and 45 years For patients : - DSM-5 criteria of schizophrenia - Patients followed as outpatients, - Age of onset of the disease less than 40 years, - Patients whose disease has stabilized: no changes psychotropic treatment for at least 1 month - Not more of a benzodiazepine, - Patients on protection of justice or not, For controls : - Matched for sex to patient - Age-matched (+/- 3 years) to patient - Matched for IQ (score fNART +/- 10% to patients - Matched for Lextale score+/- 10% to patients Exclusion Criteria: For patients : - Any other comorbid psychiatric diagnosis of Axis I DSM-5 - Extrapyramidal syndrome or tardive dyskinesia (AIMS score <2 BARS score <2 and score Simpson and Angus <3) - Calgary depression scale = 6 - Current or past addiction to all toxic substances (including alcohol and cannabis) except tobacco. - Current or past use of all toxic consumption (excluding alcohol, tobacco and cannabis). - Use of alcohol or cannabis before the age of 15 years - Alcohol abuse in the past 6 months. - Cannabis abuse in the past 6 months and cannabis use in the last 3 months. - Patients with impaired vision or hearing preventing the realization of the tests. For controls: - Any psychiatric diagnosis according to DSM-5, including addictions (excluding tobacco) - Score HADS Anxiety = 8 and Depression = 8 - SCL90R: global severity score GSI> 0.33 for women and> 0.27 for men, or score diversity PST symptoms> 18.49 for men and> 21.97 for women or score of degree of discomfort PSDI> 1.27 for men and> 1.3 for women, scoring in the subscale Psychotic Features> 0. - Presence of a personality disorder at PDQ4 + - Head injuries, brain injuries or diseases, - vision or hearing problems preventing the realization of the tests. - Current or past addiction to all toxic substances (including alcohol and cannabis) except tobacco. - Current or past use of all toxic consumption (excluding alcohol, tobacco and cannabis). - Long-term Anticholinergic treatment. - Related to the first degree diagnosed with a psychotic disorder |
Country | Name | City | State |
---|---|---|---|
France | CHU Clermont-Ferrand | Clermont-Ferrand | Auvergne |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand | Université d'Auvergne |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Semantic conflict in stroop test | The stroop effect consists of the semantic and the response conflict. In patients with schizophrenia, the stroop effect is longer than in controls. By comparing the stroop effect and the semantic conflict between patients and controls, we can determine whether the slowing observed in patients is due to a general slowdown (semantic and response conflict) or specific slowness (semantic or response conflict). | at day 1 | |
Secondary | Response conflict in stroop test | The stroop effect consists of the semantic and the response conflict. In patients with schizophrenia, the stroop effect is longer than in controls. Response conflict (time in milliseconds) is obtained by subtracting the semantic conflict (time in milliseconds obtained in the second step of the protocol) from the stroop effect (time in milliseconds obtained in the first step of the protocol). Therefore, we can determine whether the slowing observed in patients is due to a general slowdown (semantic and response conflict) or specific slowness (semantic or response conflict). |
at day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |